My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Aurobindo Pharma Ltd Research Report - 16th Nov 2016

Pharmaceutical | Published on Nov 16th 2016


Aurobindo Pharma (APL) posted numbers lower than expected on sales and net profit front, while OPM was more or less in line with expectations. On sales front, the company posted sales of Rs3715cr vs. Rs3,900cr expected vs. Rs3,280cr in 2QFY2016, posting a yoy growth of 13.3%. On the operating front, the EBITDA margin came in at 23.4% vs. 24.1% expected and vs. 22.0% in 2QFY2016. Consequently, the Adj. PAT came in at Rs606cr vs. Rs660cr expected vs. Rs454cr in 2QFY2016, a yoy growth of 33.5%. Apart from better than expected OPM, the company also posted higher than expected other income (Rs82cr in 2QFY2017 vs. Rs65cr in 2QFY2016). We maintain our Buy rating on the stock.

Download Full Report


CMP 733
Target Price 877
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others11.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo